A5006838528- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic function and diabetes
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- Renal and related cancers
- Cancer-related Molecular Pathways
- Hepatocellular Carcinoma Treatment and Prognosis
- Antioxidant Activity and Oxidative Stress
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- PI3K/AKT/mTOR signaling in cancer
- Vitamin C and Antioxidants Research
- MicroRNA in disease regulation
- Colorectal Cancer Screening and Detection
- Neuroblastoma Research and Treatments
- Colorectal Cancer Surgical Treatments
Moffitt Cancer Center
2016-2025
Cedars-Sinai Medical Center
2018
AdventHealth Tampa
2014-2017
University of South Florida
2006-2016
University of Central Florida
2016
Florida State University
2016
Anesthesiology and Surgical Oncology Research Group
2016
American Society for Gastrointestinal Endoscopy
2015-2016
National Cancer Institute
2006-2015
Sarasota Memorial Hospital
2007-2015
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible resection with curative intent those unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant cancer setting, as well management of locally advanced metastatic Clinical trials are critical making progress treatment cancer. The NCCN Guidelines Pancreatic Adenocarcinoma focus on diagnosis systemic...
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in United States. A major challenge treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Adenocarcinoma provides recommendations diagnosis, evaluation, treatment, follow-up patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities including targeted therapies, provide hope improving patient outcomes. Sections manuscript have been...
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas exocrine pancreas are intended to assist with clinical decision-making. These Insights summarize major discussion points from 2014 Panel meeting. panel focused mainly on borderline resectable locally advanced disease. In particular, discussed definition disease, role neoadjuvant therapy in chemoradiation potential newer, more active chemotherapy regimens both settings.
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas exocrine pancreas are intended to assist with clinical decision-making. These Insights important updates 2019 version guidelines, focusing on postoperative adjuvant treatment patients pancreatic cancers.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors exocrine pancreas. These Insights provide a summary explanation major changes to 2012 Adenocarcinoma. panel made 3 significant updates guidelines: 1) more detail was added regarding multiphase CT techniques diagnosis staging pancreatic cancer, pancreas protocol MRI as an emerging alternative CT; 2) use fluoropyrimidine plus oxaliplatin (e.g.,...
Purpose. Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.Material methods. We updated our institutional outcomes with a chemotherapy stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis was performed all BRPC LAPC patients treated departmental protocol. After staging, medically fit underwent for 2–3 months, regimen at the discretion treating medical oncologist. Patients then received...
In the year 2005, an estimated 31,800 people will die of pancreatic cancer in United States. This disease is fourth most common cause cancer-related death among men Its peak incidence occurs seventh and eighth decades life. Although roughly equal two sexes, African Americans appear to have a higher than white Americans. these NCCN Pancreatic Adenocarcinoma guidelines, only tumors exocrine pancreas are discussed; endocrine from islets Langerhans carcinoid not included. For recent version...
NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) there uniform consensus.Category 2A: lowerlevel 2B: nonuniform consensus (but no major disagreement).Category 3: any level but reflects disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: believes that the best management for cancer patient in a clinical trial.Participation trials especially encouraged.
To investigate whether a mindfulness-based stress reduction program for cancer (MBSR-C) improved psychological and physical symptoms, quality of life (QOL), markers among advanced-stage patients caregivers.A pilot within-subject design was used.Patients previously diagnosed with breast, colon, lung, or prostate on treatment were recruited from the Moffitt Cancer Center Research Institute. Twenty-six patient-caregiver dyads completed modified 6-week, self-study MBSR-C based Kabat-Zinn model....
<h3>Background</h3> We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors pancreatic cancer patients. <h3>Methods</h3> Tumors were minced into fragments and cultured in media containing high dose interleukin-2 (IL-2) for up to 6 weeks. T cell phenotype, activation markers, reactivity measured. <h3>Results</h3> TIL expansion was measured 19 patient samples. The majority of these CD4<sup>+</sup> cells highly activated. Purified...
Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma), gall bladder, and bile ducts (cholangiocarcinomas). Gallbladder cancer cholangiocarcinomas are collectively known as biliary tract cancers. is most common aggressive type all Cholangiocarcinomas diagnosed throughout tree typically classified either intrahepatic or extrahepatic cholangiocarcinoma. Extrahepatic more than cholangiocarcinomas. This manuscript focuses on clinical...
Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cancer precursors incidentally discovered by cross-sectional imaging. Consensus guidelines for IPMN management rely on standard radiologic features to predict pathology, but they lack accuracy. Using a retrospective cohort of 38 surgically-resected, pathologically-confirmed IPMNs (20 benign; 18 malignant) with preoperative computed tomography (CT) images and matched plasma-based 'miRNA genomic classifier (MGC)' data, we...
The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need developing personalized medicine strategies refine the current treatment decision-making process. To derive a prognostic gene signature PDAC, PDAC cohort Moffitt Cancer Center (n = 63) was used overall (OS) as primary endpoint. further evaluated using independent microarray...
Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, intraduodenal portion bile duct, and pancreatic duct), while periampullary may arise locations encompassing head pancreas, distal duodenum, or Vater. are rare gastrointestinal malignancies, prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, treatment modality received. Systemic therapy is used in all stages ampullary cancer, including neoadjuvant...
This study was designed to investigate the role of graded doses lipoic acid pretreatment against cisplatin-induced nephrotoxicity. Male Wistar rats were divided into six groups and treated as follows: 1) vehicle (saline) control; 2) cisplatin (16 mg/kg, intraperitoneally); 3) (100 4) plus (25 mg/kg); 5) (50 mg/kg) 6) mg/kg). Rats sacrificed three days after treatment, plasma well kidneys isolated analyzed. Plasma creatinine increased (677% control) following administration alone which...